|Bid||0.00 x 1000|
|Ask||0.00 x 1100|
|Day's Range||2.92 - 3.16|
|52 Week Range||2.20 - 5.85|
|Beta (3Y Monthly)||0.24|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.00|
NEW YORK, Oct. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
A look at the shareholders of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual Read More...
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved Adamis’ lower dose version (0.15mg) of Symjepi ™ for the emergency treatment of allergic reactions (Type I) including anaphylaxis. Symjepi (epinephrine) Injection 0.3mg is an FDA-approved product, for the emergency treatment of allergic reactions (Type I) including anaphylaxis, designed for patients weighing 66 pounds or greater. The lower dose version (0.15mg) is intended to potentially treat patients weighing 33-66 pounds. Both Symjepi products will provide two single-dose injections syringes of epinephrine (adrenaline), which is considered the drug of choice for immediate administration in acute anaphylactic reactions to allergic reaction to foods (such as nuts), insect stings or bites, drugs and other allergens, as well as idiopathic or exercise-induced anaphylaxis.
NEW YORK, NY / ACCESSWIRE / September 26, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Adamis Pharmaceuticals Corporation (ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy. The company's Symjepi (epinephrine) Injection 0.3mg, was approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis, and its Symjepi (epinephrine) Injection 0.15mg product is undergoing FDA review. ADMP has selected Novartis unit Sandoz to launch the product in the U.S. (the FDA approved the 0.30 mg version in November 2017).
Adamis Pharmaceuticals (ADMP) needs investors to pay close attention to the stock based on moves in the options market lately.
Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.
SAN DIEGO, Aug. 27, 2018-- Adamis Pharmaceuticals Corporation today provided a business update.. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals, said,“ We have been receiving ...
Mylan’s (MYL) epinephrine auto-injector EpiPen is approved as the first line of treatment for life-threatening allergic reaction anaphylaxis. During its second-quarter earnings release on August 8, Mylan provided an update on its EpiPen supply shortages.
Teva (TEVA) gains FDA approval for the first generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment.
NEW YORK, NY / ACCESSWIRE / August 17, 2018 / Biotech stocks Antares Pharma rose marginally and Adamis Pharmaceuticals was in the red on Thursday after news of Teva receiving FDA approval for its generic version of the EpiPen. Antares Pharma, Inc. shares closed up 4.10% on Thursday with an additional 3.33% in gains in after-hours trading. The company announced yesterday that it's partner Teva Pharmaceutical Industries has had its epinephrine auto injector drug-device combination product for emergency treatment of severe allergic reactions, approved by the Food and Drug Administration.
Today, Teva Pharmaceutical Industries (TEVA) received FDA approval for the generic version of Mylan’s (MYL) allergy products EpiPen and EpiPen Jr. The epinephrine autoinjector is used to treat allergic reactions, including life-threatening condition of anaphylaxis. The company received FDA approval for the use of the product in adults as well as children weighing more than 33 pounds. In 2016, Teva’s generic version of EpiPen was unable to secure FDA approval.
Shares of the U.S.-listed Teva Pharmaceutical Industries Ltd. (TEVA) surged 6.2% in extremely heavy Thursday afternoon trade after the company's generic version of the EpiPen allergic reaction treatment was approved by the Food and Drug Administration, making it the product's first true generic rival. Teva secured approval for both adult and child-appropriate dose levels of its generic epinephrine autoinjector. Shares of Mylan (MYL) , which sells the EpiPen and a cheaper authorized generic version, slumped 0.5% in heavy trade, while rivals Amneal Pharmaceuticals Inc. (AMRX) and Adamis Pharmaceuticals Corp. (ADMP) had shares drop 3% and 7.5% respectively.
Adamis (ADMP) delivered earnings and revenue surprises of -70.59% and -5.36%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the San Diego-based company said it had a loss of 29 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals, stated, “Recently, we have announced several significant achievements for our company. The Sandoz partnership for the commercialization and distribution of Symjepi™ in the U.S. will likely prove to be the most transformative for the Company. Under the agreement, Sandoz will take responsibility for sales and marketing.
Adamis Pharmaceuticals Corporation (ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy, announced today the closing of its previously announced underwritten public offering of 11,666,667 shares of its common stock at a public offering price of $3.00 per share, as well as 1,750,000 additional shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters. Raymond James & Associates, Inc. acted as the sole book-running manager for the offering. B. Riley FBR acted as lead manager for the offering. H.C. Wainwright & Co. and Maxim Group LLC acted as co-managers for the offering.
The offering is expected to close on August 6, 2018, subject to the satisfaction of customary closing conditions. The company has also granted the underwriters a 30-day option to purchase up to 1,750,000 additional shares of its common stock. Raymond James & Associates, Inc. is acting as the sole book-running manager for the offering. B. Riley FBR is acting as lead manager for the offering. H.C. Wainwright & Co. and Maxim Group LLC are acting as co-managers for the offering.
SAN DIEGO, Aug. 01, 2018-- Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including ...
NEW YORK, Aug. 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Horizon ...
Novartis (NVS) intends to spin off its Alcon eye care division. The CHMP gives positive opinion recommending marketing approval to several drugs.
NEW YORK, NY / ACCESSWIRE / July 3, 2018 / Adamis Pharmaceuticals shares exploded on Monday after announcing that it has found a commercial partner for its allergic reaction treatment Symjepi. Shares of MiMedx Group fell hard after Wall Street learned the company's CEO and COO have both resigned amidst an ongoing investigation in the company's business practices. Adamis Pharmaceuticals Corporation shares closed up 50% on Monday with about 11.5 million shares traded.